Dobesilate in the treatment of plaque psoriasis.
Fibroblast growth factor (FGF)-mediated pathways participate in many of the cellular events implicated in the pathogenesis of psoriasis. Thus, targeting FGF signals may be potentially therapeutic in the treatment of psoriasis. We report for the first time on a 43-year-old man with chronic-type plaque psoriasis with a daily topical treatment of dobesilate, a new FGF inhibitor. As early as at day 14, the patient had cleared or achieved excellent improvement of psoriatic skin lesions. Topical dobesilate offers the potential for treatment of plaque psoriasis without atrophy or other local side effects associated with the use of topical corticosteroids.
Cuevas
Pedro
P
Servicio de Histologia, Departamento de Investigacion, Hospital Ramon y Cajal, Ctra. de Colmenar, km. 9.100, E-28034-Madrid, Spain. pedro.cuevas@hrc.es
Arrazola
Jose M
JM
D000328:Adult; D002123:Calcium Dobesilate / Q000627:therapeutic use*; D005346:Fibroblast Growth Factors / Q000037:antagonists & inhibitors*; D006490:Hemostatics / Q000627:therapeutic use*; D006801:Humans; D008297:Male; D011565:Psoriasis / Q000188:drug therapy*
D006490:Hemostatics; D002123:Calcium Dobesilate; D005346:Fibroblast Growth Factors